newsfilter
← Latest News
PR Newswire·

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...